Compare CRNX & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | HLN |
|---|---|---|
| Founded | 2008 | 2022 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 43.7B |
| IPO Year | 2018 | N/A |
| Metric | CRNX | HLN |
|---|---|---|
| Price | $33.73 | $9.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $74.78 | N/A |
| AVG Volume (30 Days) | 1.0M | ★ 7.9M |
| Earning Date | 05-07-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $722.66 | $7.04 |
| Revenue Next Year | $183.79 | $4.58 |
| P/E Ratio | ★ N/A | $49.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.10 | $8.71 |
| 52 Week High | $57.99 | $11.42 |
| Indicator | CRNX | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 36.39 |
| Support Level | $33.23 | $9.59 |
| Resistance Level | $37.23 | $9.96 |
| Average True Range (ATR) | 1.62 | 0.14 |
| MACD | 0.13 | -0.06 |
| Stochastic Oscillator | 8.33 | 12.66 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.